KemPharm receives patent for LAT prodrug technology for Attention Deficit – Hyperactivity Disorder treatment

KemPharm, Inc. announced today that it has received a Notice of Issuance from the United States Patent and Trademark Office (USPTO) for its patent application entitled "Polar Hydrophilic Prodrugs of Amphetamine and Other Stimulants and Processes for Making and Using the Same", U.S. Patent No. 7,772,222.  This patent protects broad aspects of the Company's core Ligand Activated Therapy (LAT) prodrug technology platform and its application to the treatment of Attention Deficit – Hyperactivity Disorder.  The patent includes key related compounds to the Company's lead clinical candidate KP106, a new chemical entity (NCE) composed of the active pharmaceutical compound d-amphetamine and a ligand, which recently successfully completed a Phase 1 clinical trial.  

"This Notice of Issuance signals a major accomplishment for KemPharm as it marks the first issued patent protecting compounds related to KP106 and other ADHD drugs derived from our LAT platform," stated Travis Mickle, Ph.D., President & CSO for KemPharm.  "Obtaining this patent within four years of founding KemPharm validates our efficient approach to securing intellectual property and highlights the value of our proprietary LAT technology.  This is the first of what we anticipate to be many patents we expect to have issued that protect our products under development covering various CNS indications."  

"Intellectual property is an important strategic focus for a prodrug company like KemPharm," added Sven Guenther, Ph.D., Vice President of Research.  "Since most of our programs are designed to improve already marketed drugs, we pay particular attention to how we can differentiate our products from potential prior art before we ever synthesize a molecule utilizing LAT.  We are pleased that the USPTO has acknowledged the novel aspects and non-obvious results generated by our ADHD portfolio and granted protection of our discoveries."

Source:

KemPharm, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
New high-throughput assay could help development of anti-COVID-19 drugs